UCBs transformation into a biopharma company is complete.

The unit is led by Iris Loew-Friedrich, Executive Vice President, Biopharma Advancement Solutions and Chief Medical Officer, who also coordinates all of UCB’s medical features. The NewMedicines unit, today already in place, focuses on early study and discovery through to clinical proof concept. To be able to ensure a clean implementation of the company’s strategic priorities at the neighborhood level, UCB provides redefined its geographic responsibilities and has appointed strong UCB leaders at the head of each region.Working income for the fourth quarter of 2013 increased to $262,000, in comparison to working income for the 4th quarter of 2012 of $56,000. The full total number of techniques performed in AMS' Gamma Knife business, including Gamma Knife and Gamma Knife Perfexion procedures, increased 7 percent for the fourth quarter and 19 percent for 2013 when compared to same periods of 2012. Medical providers gross margin for the fourth quarter of 2013 was 34.3 percent, compared to medical services gross margin of 37.0 percent for the fourth quarter of 2012.